Skip to content
orbyd

Dossier · BBNX · Dormant

BBNX · Beta Bionics, Inc. · Stock research

LOW Earnings inflection Catalyst · medtech-diagnostics precision-biotech-therapeutics

Last analysed ·

Current thesis

Broken-growth AID-pump name in a pre-earnings holding pattern: the ~2026-07-28 Q2 print is the binary that decides whether new patient starts re-accelerate or post a second straight sequential decline. June's ~$14 relief bounce off the $8.80 low stalled once ADA delivered a booth and a data dashboard rather than a readout. Below every major moving average; no momentum leg to buy ahead of the print.

Invalidation trigger

A weekly close below $11 voids the relief-bounce repair off the $8.80 low and reopens that low; a second straight sequential decline in new patient starts on the ~2026-07-28 Q2 print confirms the broken-growth de-rate.

Thesis status

Open commitment catalyst in 9dscored if the trigger above fires How this is scored →

Latest analysis and events for BBNX —

As of 2026-07-11, orbyd's latest analysis for Beta Bionics, Inc. (BBNX): Broken-growth AID-pump name in a pre-earnings holding pattern: the ~2026-07-28 Q2 print is the binary that decides whether new patient starts re-accelerate or post a second straight sequential decline. June's ~$14 relief bounce off the $8.80 low stalled once ADA delivered a booth and a data dashboard rather than a readout. Below every major moving average; no momentum leg to buy ahead of the print.

Invalidation trigger: A weekly close below $11 voids the relief-bounce repair off the $8.80 low and reopens that low; a second straight sequential decline in new patient starts on the ~2026-07-28 Q2 print confirms the broken-growth de-rate.

Next dated event on file: — catalyst in 9d.

Current Thesis

Beta Bionics makes the iLet Bionic Pancreas, an automated insulin-delivery (AID) pump that doses on body weight alone with no carb counting. The growth story that carried shares from the Jan-2025 IPO at $17 to a $32.71 high broke on 2026-01-09 (~-35% in a session) when Q4-2025 new patient starts decelerated from +68% YoY toward ~+36%. Q1-2026 (reported 2026-04-21) confirmed the crack: revenue +57% YoY to $27.6M, but new patient starts fell 10-20% sequentially the metric that governs a razor-and-blade device, since installed-base supply reorders mask the top of the funnel. Shares repaired off the $8.80 low toward ~$13.88 (2026-06-19) into the early-June ADA conference, but ADA delivered a booth and a real-world-data dashboard, not a binary readout, so the relief leg lost its fuel and the tape drifted into a pre-earnings range. Price sits below every major moving average, far under the January gap. The next durable move is decided by the ~2026-07-28 Q2 print, roughly 17 days out: sequential re-acceleration in new starts turns the structure; a second straight decline resumes the de-rate. There is no trend to buy in front of it.

Bullish and bearish views on Beta Bionics, Inc.

The model's bull view on Beta Bionics, Inc. (BBNX), in brief: Pharmacy channel inflecting: Q1-2026 pharmacy-benefit sales $10.7M, +181% YoY, vs DME $16.9M +22%; pharmacy mix guided to 37-39% of FY26 new starts (2026-04-21) a higher-margin, stickier revenue base. The bear view: Front-end demand is stalling: new patient starts -10-20% sequentially Q4-2025→Q1-2026, the second leg of the +68%→+36% deceleration that broke the stock on 2026-01-09. Both cases follow in full.

Bull Case

  • Pharmacy channel inflecting: Q1-2026 pharmacy-benefit sales $10.7M, +181% YoY, vs DME $16.9M +22%; pharmacy mix guided to 37-39% of FY26 new starts (2026-04-21) a higher-margin, stickier revenue base.
  • Margin step-up: Q1 gross margin 59.5%, +864 bps YoY; FY26 GM guide raised to 57.5-59.5% from 55.5-57.5% (2026-04-21).
  • Type 2 optionality: 25-30% of Q1 new starts came from Type 2 patients with no explicit T2 label; ADA's 2026 guidelines now name AID as standard of care for Type 2, a TAM expander if a label follows.
  • Balance sheet covers the burn: $239.5M cash and investments at 2026-03-31 against ~$70M annual cash burn no near-term raise pressure.
  • Sell-side still constructive: Goldman maintains Buy, PT cut to $17 on 2026-05-27, ~23% above the ~$13.88 tape; broader consensus PTs span $14 to $28-32.
  • Transparency push: near-real-time iLet outcomes dashboard went live 2026-06-02 (publishes all patients meeting two pre-stated criteria, no exclusions), a defense of the clinical narrative.
  • Pipeline: Mint tubeless, phone-free patch pump guided to full commercialization end-Q2-2027 (FDA-pending); Phase 2a bihormonal glucagon feasibility trial running in New Zealand.

Bear Case

  • Front-end demand is stalling: new patient starts -10-20% sequentially Q4-2025→Q1-2026, the second leg of the +68%→+36% deceleration that broke the stock on 2026-01-09. Supply reorders flatter reported revenue while the funnel narrows.
  • Guidance implies a ceiling: FY26 revenue raised only to $131-136M from $130-135M (2026-04-21), barely above the ~$128M Q4 annualized run-rate minimal sequential growth baked in.
  • Deeply lossmaking: Q1 net loss $21.9M (-$0.49/sh vs -$0.48 est), operating loss $24.3M, adjusted EBITDA -$17.7M. Single-product lossmaking med-tech de-rates hard once growth slows.
  • Competitive squeeze widening: Insulet's Omnipod 5 led US and European new patient starts in 2025 with 600K+ active users and remains the only AID cleared for Type 2 in the US. The new ADA Type 2 standard-of-care recommendation accrues to labeled products first; iLet's Type 2 starts stay off-label. Tandem (Mobi, t:slim X2) and Medtronic (780G) round out an entrenched field.
  • Litigation overhang: securities investor-loss investigations (Robbins LLP Jun 2-3, Johnson Fistel Jun 4-5) over the Jan-2026 slower-start disclosures a capitulation-phase marker rather than a dated catalyst.
  • GLP-1 overhang: expanding GLP-1 adoption keeps a structural question mark over long-run insulin-pump TAM.

Setup & Price Structure

Peak-to-trough $32.71 → $8.80 is roughly -73%; the IPO at $17 sits well above the current tape. The repair to ~$13.88 (2026-06-19) recovered ~58% off the low yet leaves shares ~58% under the high, below every major moving average, with the January breakdown gap far overhead as resistance. The bounce got overbought into ADA and faded once the event passed with no readout, leaving a pre-earnings drift. The ~$11 area is the operative shelf: it is the floor of the June repair and the line that separates "relief base" from "back toward $8.80." This is the value-trap quadrant ~2x EV/2026 sales on a 57% grower screens cheap, but the price structure is rolled over and the growth metric is decelerating. Cheapness here is a function of a broken funnel, not a mispricing to fade. Averaging into the $8.80 low is the exact error this structure sets up.

Catalyst Calendar (next 30 days)

  • ~2026-07-28 (est.) Q2-2026 earnings. The binary. Watch new patient starts (sequential), pharmacy mix vs the 37-39% guide, and any FY26 revenue revision. Now ~17 days out; the last trading days ahead of it carry full event-risk.
  • Ongoing securities-litigation investor-loss investigations (Robbins LLP, Johnson Fistel); headline-sensitive sentiment overhang with no scheduled readout.
  • None in window no FDA/PDUFA date inside 30 days; Mint commercialization is guided end-Q2-2027.

What Would Change Our Mind

  • Bull flip: the Q2 print shows new patient starts back in sequential growth and pharmacy mix hitting the 37-39% guide narrative repair, and the name becomes a base-and-breakout candidate rather than a broken laggard.
  • Bear confirmation: a second straight sequential decline in new starts resumes the de-rate and puts $8.80 back in play, regardless of the reported revenue headline.
  • Structural: a weekly close below $11 voids the June repair; a weekly close that reclaims the January gap zone would be the first evidence of a genuine trend turn rather than a relief bounce.

Correlation Notes

  • Moves with the AID/diabetes-device complex PODD (Insulet), TNDM (Tandem), MDT (Medtronic 780G) but as the decelerating laggard it tends to underperform the group on up-days and lead it lower on risk-off.
  • Inverse sentiment linkage to the GLP-1 names (LLY, NVO) via the insulin-delivery TAM debate.
  • Small-cap, single-product med-tech beta: illiquid, short-interest-prone, and largely index-uncorrelated on print day, when the stock trades on its own new-start number.
  • Litigation headlines drive idiosyncratic moves independent of the tape.

Notes

  • Core metric to watch is NEW PATIENT STARTS, not revenue installed-base supply sales mask front-end demand. Q1 starts fell 10-20% sequentially; that is the whole bear case.
  • Q2 2026 earnings (~late Jul/early Aug, est.) is the binary outside the 30-day catalyst window. Treat any pre-print position as event-risk.
  • Securities-litigation 'investor loss' investigations launched Jun 3 2026 (Johnson Fistel) sentiment overhang, not a dated catalyst, but flags retail capitulation phase.
  • Mint patch pump full commercialization guided to end-Q2 2027, subject to FDA clearance too far out to anchor a trade.
  • Cash $239.5M vs ~$70M annual cash burn = no near-term raise pressure; not a solvency story, a growth-deceleration story.
  • This is the value-trap quadrant: cheap-ish (~2x EV/sales on a 57% grower) but rolled-over structure. Do not average down into the $8.80 low.
  • Core metric is NEW PATIENT STARTS, not revenue installed-base supply reorders mask front-end demand. Q1 starts fell 10-20% sequentially; that is the entire bear case.
  • Q2-2026 earnings (~late Jul/early Aug, est.) is the binary that decides re-acceleration vs second straight sequential decline. Outside the 30-day window any pre-print position is event-risk.
  • ADA 86th Scientific Sessions Jun 5-8 2026 (New Orleans) is a SOFT catalyst booth + real-world-data dashboard, no scheduled binary readout. The ~+7% pre-ADA bounce is relief off a broken base, not a trend turn.
  • Insider sells 2026-06-03 (CEO Saint 16,872 sh, CFO Feider 6,676, CCO Hopman 5,329, CPO Mensinger 4,378, CMO Russell 4,222) were RSU tax-withholding mechanical, not discretionary bearish signals. Do not over-read.
  • Securities-litigation investor-loss investigations escalating (Robbins LLP Jun 2-3, Johnson Fistel Jun 4-5) over the Jan-2026 slower-start disclosures sentiment overhang and capitulation-phase marker, not a dated catalyst.
  • Value-trap quadrant: ~2x EV/2026 sales on a 57% grower reads cheap, but structure is rolled over. Do NOT average down into the $8.80 52-week low.
  • Cash $239.5M (2026-03-31) vs ~$70M annual burn = no near-term raise pressure. This is a growth-deceleration story, not a solvency story.
  • Mint patch pump full commercialization guided end-Q2-2027 (FDA-pending) too far out to anchor a trade.
  • Core metric is NEW PATIENT STARTS, not revenue installed-base supply reorders mask front-end demand. Q1-2026 starts fell 10-20% sequentially; that is the entire bear case.
  • Q2-2026 earnings ~2026-07-28 (est.) is the binary deciding re-acceleration vs a second straight sequential decline. It sits ~37 days out just outside the 30-day window so any pre-print position is event risk into a 20%+ implied move.
  • iLet's 25-30% Type 2 starts remain OFF-LABEL the label advantage accrues to the competitor.
  • Value-trap quadrant: ~2x EV/2026 sales on a ~57% grower screens cheap, but structure is rolled over below all major MAs. Do not average down into the $8.80 low.
  • Insider context: 2026-06-04 director Christy Jones open-market sale 2,811 sh @ $14.00 (10b5-1, planned) is real supply near recovery highs; distinct from the 2026-06-03 RSU tax-withholding sells which were mechanical do not conflate.
  • Cash $239.5M vs ~$70M annual burn = no near-term raise pressure. This is a growth-deceleration story, not a solvency story.
  • Securities-litigation investor-loss investigations (Johnson Fistel, Robbins LLP) over the Jan-2026 slower-start disclosures are a sentiment overhang and capitulation marker, not a dated catalyst.
  • Mint patch pump guided to full commercialization end-Q2-2027 (FDA-pending) too far out to anchor a trade.
  • Core metric is NEW PATIENT STARTS, not reported revenue installed-base supply reorders flatter the top line and mask front-end demand. Q1-2026 starts fell 10-20% sequentially; that is the entire bear case.
  • Earnings blackout: ~2026-07-28 (est.) Q2 print is the binary. As of 2026-07-11 it is ~17 days out inside the 30-day window but not yet the <3-day binary-risk zone. Any position taken into the last trading days pre-print is event-risk, not a momentum trade.
  • ADA 86th Scientific Sessions (2026-06-05 to 06-08) was a SOFT catalyst booth + real-world-data dashboard, no scheduled readout. The pre-ADA bounce was relief off a broken base, not a trend turn, and it has now elapsed.
  • Securities-litigation investor-loss investigations (Robbins LLP Jun 2-3, Johnson Fistel Jun 4-5) over the Jan-2026 slower-start disclosures are a sentiment overhang and capitulation-phase marker, not a dated catalyst.
  • June-2026 insider sells (CEO Saint 16,872 sh, CFO Feider 6,676, CCO Hopman 5,329, CPO Mensinger 4,378, CMO Russell 4,222) were RSU tax-withholding mechanical, not discretionary bearish signals.
  • Value-trap quadrant: ~2x EV/2026 sales on a 57% grower reads cheap, but the structure is rolled over. Do not average down into the $8.80 low.
  • Mint tubeless patch pump full commercialization guided to end-Q2-2027 (FDA-pending) too far out to anchor a trade.
  • $239.5M cash/investments at 2026-03-31 vs ~$70M annual burn = no near-term raise pressure; a growth-deceleration story, not a solvency story.

Related · shared themes

HNGE

Hinge Health, Inc.

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.

LOW

TXG

10x Genomics, Inc.

Stalled single-cell franchise re-rating on the spatial/multiomics pivot: Atera (ships H2 2026), Proteintech protein capability, and a Cleveland Clinic clinical tie-up extend the story while a July cluster of analyst target raises ($40–$50) chases the tape. Atera revenue is a 2027 event and the name is overbought above consensus the 2026-08-06 Q2 print is the next real test.

LOW

ASTS

AST SpaceMobile, Inc.

The July 15-16 $1B convertible plus the slip of initial commercial direct-to-device service into 2027 broke the "2H26 revenue" leg the June rebound was built on; a 17% one-day flush to $55.01 and a fading +12% bounce mark this as a funded-but-delayed story trading on retail flow, with the 7/22 FCC licensing vote the only near-term catalyst.

LOW

BFLY

Butterfly Network, Inc.

Butterfly Embedded chip-licensing story got marquee validation Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the June double has stalled and news thinned; a binary Q2 print (~early Aug) is now the next input and the easy momentum leg is spent.

LOW

See also · stocks to watch

medtech stocks to watch